Both EZH2 and BRD4 can be targeted by selective and potent small molecule inhibitors [19, 20] that are currently being evaluated in clinical trials making them appealing targets for the treatment of MPNST. Here, BRD4 is linked to malignant peripheral nerve sheath tumor.